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Abstract: This pilot study aims to investigate whether salivary small extracellular vesicle
(sEV)-associated microRNAs could act as potential biomarkers for periodontal disease status.
Twenty-nine participants (10 who were healthy, nine with gingivitis, 10 with stage III/IV periodontitis)
were recruited and unstimulated whole saliva samples were collected. Salivary sEVs were isolated
using the size-exclusion chromatography (SEC) method and characterised by morphology, EV-protein
and size distribution using transmission electron microscopy (TEM), Western Blot and Nanoparticle
Tracking Analysis (NTA), respectively. Ten mature microRNAs (miRNAs) in salivary sEVs and saliva
were evaluated using RT-qPCR. The discriminatory power of miRNAs as biomarkers in gingivitis
and periodontitis versus healthy controls was evaluated by Receiver Operating Characteristics (ROC)
curves. Salivary sEVs were comparable to sEVs morphology, mode, size distribution and particle
concentration in healthy, gingivitis and periodontitis patients. Compared to miRNAs in whole saliva,
three significantly increased miRNAs (hsa-miR-140-5p, hsa-miR-146a-5p and hsa-miR-628-5p) were
only detected in sEVs in periodontitis when compared to that of healthy controls, with a good
discriminatory power (area under the curve (AUC) = 0.96) for periodontitis diagnosis. Our study
demonstrated that salivary sEVs are a non-invasive source of miRNAs for periodontitis diagnosis.
Three miRNAs that are selectively enriched in sEVs, but not whole saliva, could be potential biomarkers
for periodontal disease status.
Keywords: salivary small extracellular vesicles; size exclusion chromatography; miRNAs; periodontal
disease; biomarker discovery
1. Introduction
Periodontitis is a complex inflammatory disease, associated with a dysbiotic plaque biofilm and
characterised by the destruction of periodontal tissues. Currently, it is clinically diagnosed by clinical
attachment loss (CAL), periodontal pocket depth (PPD), bleeding on probing (BOP) and radiographic
bone loss. Aside from the fact that these parameters are mostly measures of past disease activity
and, in the case of BOP, have poor predictive properties for disease progression, they also require
professional dental assessment. Given the widespread incidence of periodontitis in approximately 50%
of the global adult population [1], there is a plausible rationale for the development of a biologically
based non-invasive diagnostic system for periodontal disease status.
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Human saliva is an attractive source of biomarkers for periodontitis; it is easy to access
through non-invasive means, is low-cost, and potentially provides a “mirror” of the periodontal
status of a patient [2,3]. Salivary levels of pro-inflammatory cytokines [4,5], chemokines [6],
matrix metalloproteinases [7,8] and bone remodelling proteins [4,9–11] have been investigated for
their ability to distinguish between individuals with periodontal disease and those who are healthy.
However, most proteins are present in low concentrations in saliva and have a limited diagnostic value
due to their poor sensitivity and specificity [11].
In the past 10 years, the role of extracellular vesicles (EVs) in cell-to-cell communication has been
widely explored [12]. EVs are lipid-encapsulated vesicles with the capacity to transport bioactive
molecules (i.e., microRNAs (miRNAs)) which can be delivered to other cells to regulate their biological
function. There are several types of EVs, which can be classified by their sizes, into small EVs
(i.e., sEVs, exosomes), medium (i.e., microvesicles) and large EVs (i.e., macrovesicles and apoptotic
bodies). Currently, there is an ongoing discussion in the literature about the heterogeneity of EVs
and the correct nomenclature; however, the majority of studies have focused on small EVs such as
exosomes. sEVs (< 200 nm), which are abundant in saliva and are emerging as a potential source for the
development of diagnostic tools for a variety of diseases [13–16], owing to their components—nucleic
acids (microRNAs, DNAs and other RNAs), lipids and proteins. Salivary sEVs have not been widely
explored as a diagnostic tool in periodontology, probably because the methodology for their isolation
is still developing. Very recent research has demonstrated that salivary CD9- and CD81-positive
(two tetraspanin proteins enriched in EVs) sEVs are decreased in periodontitis compared to healthy
controls [17]. Other recent research has demonstrated that the salivary sEV (exosomal) programmed
death-ligand 1 (PD-L1) mRNA is significantly increased (p < 0.01) in periodontitis patients versus
non-periodontitis subjects [18].
sEVs can carry a wide range of bioactive molecules and are enriched in small non-coding
RNAs [19]. MicroRNAs (miRNAs) are non-coding RNAs, 19–25 nucleotides in length. Very recent
research has demonstrated that miR-512-3p and miR-412-3p were upregulated in salivary sEVs from
oral squamous cell carcinoma patients compared to the controls [20]. However, no studies have
explored miRNAs’ expression patterns in salivary sEVs as potential biomarkers for periodontal
status. According to published reviews [21–26], ten periodontitis-associated miRNAs (hsa-miR-15a-5p,
hsa-miR-29b-3p, hsa-miR-124-3p, hsa-miR-140-5p, hsa-miR-146a-5p, hsa-miR-148a-3p, hsa-miR-155-5p,
hsa-miR-223-3p, hsa-miR-301b, hsa-miR-628-5p) have been explored as potential periodontitis
biomarkers from one or more sample sources, such as saliva, gingival tissues, or periodontium-derived
cells. However, since miRNAs are expressed in a tissue and biofluid-specific manner, it is important to
investigate whether these proposed miRNA periodontitis biomarker candidates are also expressed in
salivary sEVs. Additionally, whether salivary sEV-associated miRNAs have the same profile as whole
saliva-associated miRNAs in periodontitis remains unknown.
This pilot study aimed to evaluate the miRNA expression profile of whole saliva and salivary
sEVs obtained from gingivitis, periodontitis and periodontally healthy patients, and to determine the
diagnostic potential of miRNAs associated with sEVs as biomarkers of periodontal status.
2. Results
2.1. Demographic and Clinical Characteristics of the Study Groups
As shown in Table 1, the participants (n = 29) were from various ethnic backgrounds
(caucasian, Asian, and others) and mixed-gender (20 males, nine females), with ages ranging from 23
to 75. It is noted that most of the participants are non-smokers and there is an age difference between
non-periodontitis and periodontitis patients.
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Male 6 (60%) 7 (78%) 7 (70%)
Female 4 (40%) 2 (22%) 3 (30%)
Age 35.4 ± 2.4 (26–48) 31.8 5 ± 1.6 (23–40) p > 0.99 52.5 ± 4 (38–75) p = 0.01
Numbers of Teeth 27.1 ± 1.2 27.4 ± 1.1 p = 0.95 25.5 ± 3.4 p = 0.25
Smoking habit Non-smokers 10 (100%) 10 (100%) 9 (90%)
Smokers 0 0 1 (10%)
Ethnicity
Caucasians 5 (50%) 3 4 (40%)
Asians 4 (40%) 5 (55%) 6 (60%)
Others 1 (10%) 1 0
BOP 12.5% ± 1.14(6–17%)
43.6% ± 5.33 (26–70%)
p = 0.0001
43.7% ± 5.2 (20–71%)
p < 0.0001
No. of deep pockets 31.3 ± 7.34(5–66)
Average PPD (mm) · 4.9 ± 0.4(2.5–6.4)
Periodontitis
classification
Localised (< 30%) 3 (30%)
Generalised (≥30%) 7 (70%)
Grade B 6 (60%)
Grade C 4 (40%)
Stage III 9 (90%)
Stage IV 1 (10%)
Note: p values were calculated versus healthy controls.
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2.2. Salivary sEVs Characteristics
Transmission electron microscopy (TEM) analysis confirmed that the salivary sEVs were
cup-shaped (Figure 1a) and Western Blot analysis demonstrated the expression of the sEV-associated
proteins ALG-2 interacting protein X (ALIX) and CD9 (Figure 1b). Nanoparticle Tracking Analysis
(NTA) results showed that the sEVs’ average modes (Figure 1c) and particle numbers (Figure 1d) were
comparable between the healthy, gingivitis and periodontitis groups. Regarding the size distribution,
it was noted that the sEV concentration for the size range of 50–150 and 150–200 nm was slightly
increased in the periodontitis patients compared to that of the healthy controls; however, the difference
was not statistically significant (Figure 1e). There was no significant difference in terms of total protein
for salivary sEVs (f) and the ratio of salivary sEV particles/total protein (g) between the healthy,
gingivitis and periodontitis groups.
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Figure 1. Characterisation of isolated salivary small extracellular vesicles (sEVs) by morphology using 
transmission electron microscopy (TEM) (a), by sEV-related proteins (ALIX and CD9) using Western 
blotting (WB) (b) and by particle mode (c), concentration (d), size distribution using Nanoparticle 
Tracking Analysis (NTA) (e), protein (f) and particle/ug protein (g). No significant difference vs 
healthy group (ns). 
2.3. miRNAs Expression Pattern in sEVs and Saliva 
The expression of 10 miRNAs (hsa-miR-15a-5p, hsa-miR-29b-3p, hsa-miR-124-3p, hsa-miR-140-
5p, hsa-miR-146a-5p, hsa-miR-148a-3p, hsa-miR-155-5p, hsa-miR-223-3p, hsa-miR-301b, hsa-miR-
628-5p) was evaluated in salivary sEVs and whole unstimulated saliva in healthy, gingivitis and 
periodontitis patients (Figure 2). The analysis showed that three miRNAs (hsa-miR-140-5p (p < 0.05; 
Figure 2 d), hsa-miR-146a-5p (p < 0.05; Figure 2 e), hsa-miR-628-5p (p < 0.001; Figure 2 j) were 
significantly upregulated in the salivary sEVs in periodontitis compared to the healthy controls. Both 
hsa-miR-140-5p (Figure 2 d) and hsa-miR-628-5p (Figure 2 j) showed a significant difference (p < 0.05) 
in salivary sEVs between gingivitis and periodontitis. No statistically significant differences were 
found between the healthy and gingivitis groups for any of the miRNAs that were assessed. In the 
saliva-only comparison, only hsa-miR-124-3p (Figure 2 c) was significantly increased (p < 0.05) in the 
periodontitis compared to the healthy groups. All of the other miRNAs showed no statistically 
significant changes in either sEVs or saliva samples between the healthy, gingivitis and periodontitis 
groups. 
Figure 1. Characterisation of isolated salivary small extracellular vesicles (sEVs) by morphology using
transmission electron microscopy (TEM) (a), by sEV-related proteins (ALIX and CD9) using Western
blotting (WB) (b) and by particle mode (c), concentration (d), size distribution using Nanoparticle
Tracking Analysis (NTA) (e), protein (f) and particle/ug protein (g). No significant difference vs healthy
group (ns).
2.3. miRNAs Expression Pattern in sEVs and Saliva
The expression of 10 miRNAs (hsa-miR-15a-5p, hsa-miR-29b-3p, hsa-miR-124-3p, hsa-miR-140-5p,
hsa-miR-146a-5p, hsa-miR-148a-3p, hsa-miR-155-5p, hsa-miR-223-3p, hsa-miR-301b, hsa-miR-628-5p)
was evaluated in salivary sEVs and whole unstimulated saliva in healthy, gingivitis and periodontitis
Int. J. Mol. Sci. 2020, 21, 2809 5 of 13
patients (Figure 2). The analysis showed that three miRNAs (hsa-miR-140-5p (p < 0.05; Figure 2d),
hsa-miR-146a-5p (p < 0.05; Figure 2e), hsa-miR-628-5p (p < 0.001; Figure 2j) were significantly
upregulated in the salivary sEVs in periodontitis compared to the healthy controls. Both hsa-miR-140-5p
(Figure 2d) and hsa-miR-628-5p (Figure 2j) showed a significant difference (p < 0.05) in salivary sEVs
between gingivitis and periodontitis. No statistically significant differences were found between the
healthy and gingivitis groups for any of the miRNAs that were assessed. In the saliva-only comparison,
only hsa-miR-124-3p (Figure 2c) was significantly increased (p < 0.05) in the periodontitis compared to
the healthy groups. All of the other miRNAs showed no statistically significant changes in either sEVs
or saliva samples between the healthy, gingivitis and periodontitis groups.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 12 
 
 
Figure 2. The relative expression levels of microRNAs (miRNAs): hsa-miR-15a-5p (a), hsa-miR-29b-
3p (b), hsa-miR-124-3p (c), hsa-miR-140-5p (d), hsa-miR-146a-5p (e), hsa-miR-148a-3p (f), hsa-miR-
155-5p (g), hsa-miR-223-3p (h), hsa-miR-301b (i) and hsa-miR-628-5p (j) miRNA detected by qRT-PCR 
in salivary sEVs and saliva samples from gingivitis, periodontitis patients, compared to healthy 
subjects. No significant difference vs healthy group (ns). * p < 0.05 vs healthy group; *** p < 0.0002 vs 
healthy control. 
2.4. Discriminatory Power of Upregulated miRNAs in Salivary sEVs 
Receiver Operating Characteristics (ROC) curves were used to examine the discriminatory 
power of the three upregulated miRNAs as potential biomarkers for periodontitis compared to 
healthy patients (Figure 3). The ROC curves are representative of the sensitivity (true positive rate: 
Y-axis) and one-specificity (false positive rate: X-axis), while the area under the curve (AUC) indicates 
the discriminatory power of the biomarkers. 
Figure 2. The relative expression levels of microRNAs (miRNAs): hsa-miR-15a-5p (a), hsa-miR-29b-3p
(b), hsa-miR-124-3p (c), hsa-miR-140-5p (d), hsa-miR-146a-5p (e), hsa-miR-148a-3p (f), hsa-miR-155-5p
(g), hsa-miR-223-3p (h), hsa-miR-301b (i) and hsa-miR-628-5p (j) miRNA detected by qRT-PCR in
salivary sEVs and saliva samples from gingivitis, periodontitis patients, compared to healthy subjects.
No significant difference vs healthy group (ns). * p < 0.05 vs healthy group; *** p < 0.0002 vs
healthy control.
2.4. Discriminatory Power of Upregulated miRNAs in Salivary sEVs
Receiver Operating Characteristics (ROC) curves were used to examine the discriminatory power
of the three upregulated miRNAs a potential biomarkers for periodontitis compared to he lthy
patients (Figure 3). The ROC curves are represen ative of the sensitivity (true positive rate: Y-axis)
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and one-specificity (false positive rate: X-axis), while the area under the curve (AUC) indicates the
discriminatory power of the biomarkers.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 6 of 12 
 
 
Figure 3. Discriminatory power of upregulated miRNAs hsa-miR-140-5p (a–c), hsa-miR-146a-5p (d–
f), hsa-miR-628-5p (g–i) and the miRNA panel (j-l) in salivary sEVs from periodontally healthy, 
gingivitis and periodontitis patients by using Receiver Operating Characteristics (ROC) curves and 
area under the curve -AUC. Note: Row 1 and 2 show discriminatory power between periodontitis or 
gingivitis vs periodontal health of whole saliva miRNA (a, d, g, j) and sEV mRNA (b, e, h, k); Row 3 
(c, f, i, j) shows the discriminatory power of upregulated miRNAs in saliva and sEVs between 
gingivitis and periodontitis patients. 
The data show that hsa-miR-140-5p (AUC = 1, b), hsa-miR-146a-5p (AUC = 0.97, e), hsa-miR-628-
5p (AUC = 0.93, h) in salivary sEVs performed better in discriminating between periodontitis and 
health compared to saliva (AUC = 0.57, 0.56, 0.73 respectively) (Figure 3 a, d, g). Moreover, hsa-miR-
146a-5p (AUC = 0.81, e) and hsa-miR-628-5p (AUC = 0.91, h) in salivary sEVs showed the same trend 
in gingivitis compared to healthy patients. The panel of all three miRNAs showed a high AUC value 
at 0.96 in sEVs for periodontitis and a moderate AUC value at 0.78 in sEVs for gingivitis, compared 
to the healthy controls (Figure 3 d). 
Comparing gingivitis and periodontitis (c, f, i, l), all three miRNAs in sEVs performed better in 
discriminating between gingivitis and periodontitis, compared to saliva. 
3. Discussion 
This pilot study is the first to investigate the diagnostic potential of salivary sEV-associated 
miRNAs in periodontal disease. The overall objective was to determine the diagnostic value of 
miRNAs obtained from sEVs compared to those sourced from whole saliva in terms of discriminating 
Figure 3. Discriminatory power of upregulated miRNAs hsa-miR-140-5p (a–c), hsa-miR-146a-5p
(d–f), hsa-miR-628-5p (g–i) and the miRNA panel (j–l) in salivary sEVs from periodontally healthy,
gingivitis and periodontitis patients by using Receiver Operating Characteristics (ROC) curves and
area under the curve -AUC. Note: Row 1 and 2 show discriminatory power between periodontitis
or gingivitis vs periodontal health of whole saliva miRNA (a,d,g,j) and sEV mRNA (b,e,h,k); Row 3
(c,f,i,j) shows the discriminatory power of upregulated miRNAs in saliva and sEVs between gingivitis
and periodontitis patients.
The data show that hsa-miR-140-5p (AUC = 1, b), hsa-miR-146a-5p (AUC = 0.97, e), hsa-miR-628-5p
(AUC = 0.93, h) in salivary EVs performed better in discriminating between periodontitis and health
compared to saliva (AUC = 0.57, 0.56, 0.73 resp ctively) (Figure 3a,d,g). Mor ov r, hsa-miR-146a-5p
(AUC = 0.81, e) and hsa-miR-628-5p (AUC = 0.91, h) in salivary sEVs showed the same trend in
gingivitis compared to he lthy p tients. The anel of all three miRNAs showed a high AUC value at
0.96 in sEVs for periodontitis and a mod rate AUC value at 0.78 in sEVs for gingivitis, compared to the
healthy controls (Figure 3 ).
Comparing gingivitis and periodontitis (c, f, i, l), all three miRNAs in sEVs performed better in
discriminating between gingivitis and periodontitis, compared to saliva.
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3. Discussion
This pilot study is the first to investigate the diagnostic potential of salivary sEV-associated
miRNAs in periodontal disease. The overall objective was to determine the diagnostic value of miRNAs
obtained from sEVs compared to those sourced from whole saliva in terms of discriminating between
different periodontal status. It was shown that three miRNAs (hsa-miR-140-5p, hsa-miR-146a-5p,
hsa-miR-628-5p) were highly significantly upregulated (p < 0.05) in salivary sEVs from periodontitis
compared to healthy controls, with all three showing high discriminatory power at AUC > 0.9,
which suggests that they are potential biomarkers for periodontitis. Conversely, in the whole
saliva samples, only one miRNA showed a moderately statistically significant increase (p < 0.05) in
periodontitis compared to healthy patients, and the discriminatory power of this sole miRNA was
low. Therefore, it appears that miRNAs sourced from sEVs have superior potential compared to whole
saliva samples as diagnostic biomarkers of periodontal disease status.
The utilization of sEVs for both therapeutic and diagnostic applications is a rapidly developing field,
with continual refinement of isolation methods. In particular, stem cell-derived sEVs have been explored
as a promising cell-free regenerative medicine strategy for bone tissue engineering [27,28]. The two
published studies reporting on salivary sEV research in the periodontal field used a precipitation-based
ExoQuick kit [17,18], which has the potential to produce protein and nucleic acid contamination [29].
Size exclusion chromatography (SEC) has been proposed for sEV isolation with high purity and higher
functionality [30], and was applied in the current study. It should also be noted that the current study
also addressed several shortcomings noted in the existing literature investigating sEVs for periodontal
diagnostic purposes [17,18], as the sEVs in the current study were appropriately characterised according
to the newly published guidelines [31].
MicroRNAs (miRNAs) are a group of endogenous non-coding small RNAs, 19–25 nucleotides in
length, that play an important role in development, cell differentiation, proliferation and survival [32].
A single miRNA is capable of suppressing the translation of hundreds of genes by targeting the specific
3′-UTR regions of their mRNAs. Thus, there is now compelling evidence that miRNAs are associated
with physiological and pathological process that contribute to the development and progression of
systemic diseases, such as cancers [33] and vascular disease [34], as well as periodontal disease [22,35].
Several studies described the potential of miRNAs as putative diagnostic biomarkers for periodontal
disease, including hsa-miR-15a-5p, hsa-miR-29b-3p, hsa-miR-124-3p, hsa-miR-140-5p, hsa-miR-146a-5p,
hsa-miR-148a-3p, hsa-miR-155-5p, hsa-miR-223-3p, hsa-miR-301b, hsa-miR-628-5p [21–26]. It has been
reported that hsa-miR-140-5p and hsa-miR-628-5p in gingival crevicular fluid are potential diagnostic
biomarkers for periodontitis [25]. Evidence demonstrated hsa-miR-146a-5p might serve as an indicator
for periodontal disease severity in both gingival tissues [36] and saliva [37]. However, no report
has described miRNA expression in salivary sEVs from healthy, gingivitis and periodontitis patients.
Our RT-qPCR results demonstrated that hsa-miR-140-5p, hsa-miR-146a-5p and hsa-miR-628-5p were
only significantly enriched in salivary sEVs, but not whole saliva, from periodontitis samples compared
to controls. Interestingly, both hsa-miR-140-5p and hsa-miR-628-5p in salivary sEVs, but not whole
saliva, were able to differentiate between gingivitis and periodontitis (p < 0.05 in Figures 2d and 3e).
These data on salivary sEVs are in line with other recent reports [26,36,37].
To better evaluate the discriminatory power of the upregulated miRNAs as gingivitis and
periodontitis biomarkers (compared to periodontal health), we generated ROC curves. Notwithstanding
the limited patient numbers, our data showed the high discriminatory power of hsa-miR-140-5p,
hsa-miR-628-5p and hsa-miR-146a-5p, where all three miRNAs resulted in a high AUC value
(AUC > 0.9) for periodontitis diagnosis, indicating that these three miRNAs in salivary sEVs are good
predictors and can be suggested as new candidate biomarkers for periodontitis. Notably, the results
from this study indicate that hsa-miR-140-5p and hsa-miR-146a-5p in sEVs can discriminate between
healthy and periodontitis patients only, while hsa-miR-628-5p could be potential biomarkers for both
gingivitis and periodontitis, compared to healthy controls. These three miRNAs as a panel may be a
good indicator for periodontal disease (gingivitis and/or periodontitis). Moreover, hsa-miR-140-5p
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(AUC = 1 in Figure 3c) in sEVs (but not whole saliva) could be a potential marker to discriminate
between gingivitis and periodontitis patients.
These findings suggest that sEVs may provide a superior diagnostic oral liquid biopsy, because
they may be more enriched and more representative of the local environment compared to whole
saliva, which is more influenced by systemic conditions. Notably, the periodontal status did not alter
the sEVs’ modes, concentrations, protein quantities or size distribution.
As this was a pilot study with limited participant numbers, further studies will be required
using larger sample sizes. The scarcity of research in this field precluded a meaningful sample size
calculation, and the reported differences in the candidate biomarker miRNA expression in this pilot
study can be used to calculate an appropriate sample size for future studies. A limitation of this
study that needs to be addressed is the age discrepancy between the different groups, so that age can
be removed as a potential confounding factor. Ideally, biomarkers that can discriminate with high
sensitivity and specificity between health, gingivitis and periodontitis need to be identified. Small
RNA deep sequencing would be helpful to determine more robust miRNA candidate biomarkers in
salivary sEVs that can discriminate between periodontal statuses.
Taken together, based on the results and limitations in this study, our study used the SEC method
to obtain enriched salivary sEVs and three upregulated miRNAs were detected in salivary sEVs from
periodontitis patients only, compared to healthy patients.
4. Materials and Methods
4.1. Participants Recruitment and Sample Collection
Ethics approval for this study was obtained from The University of Queensland Human Ethics
Committee (approval number: 2018001225, 12/11/2018). Healthy (n = 10), gingivitis (n = 9) and
periodontitis (n = 10) participants were recruited with signed consent forms. As this was a pilot
study, a sample size calculation was not undertaken, largely because there is a scarcity of data in
this field for a meaningful calculation. Comprehensive periodontal examinations were performed
by two independent periodontists for each participant to determine their periodontal pocket depths
(PPD) and bleeding on probing (BOP). Periodontal status was defined based on recent guidelines [38]
and according to the following criteria: a) healthy: without periodontal disease history; PPD < 4
mm; BOP < 20 % sites; b) gingivitis: generalised gingival inflammation without periodontal pocket,
PPD < 4 mm; BOP > 20 % sites; c) stage III/IV periodontitis: > 30% of the sites with PPD with BOP and
six sites PPD ≥ 6 mm on at least three teeth. All participants were non-smokers, had no underlying
systemic diseases, and were not currently receiving any oral or periodontal treatment. The demographic
and clinical characteristics of the study cohort are shown in Table 1.
Whole unstimulated saliva was collected from participants as described previously [39].
The participants were asked to refrain from eating and drinking for at least 1 h prior to spitting
the saliva samples into a tube and the samples were collected in the morning (9–12 a.m.). Fresh saliva
samples were aliquoted and frozen in a −80 ◦C freezer.
4.2. Salivary sEVs Isolation
Commercially available SEC columns (miniPURE-EVs, HansaBioMed, Lonza, QLD, Australia)
were used to fractionate the saliva sample according to the manufacturer’s protocol. Briefly, 250 µL of
saliva was diluted in 250 µL of Dulbecco’s Phosphate Buffered Saline (DPBS, 1×, without Calcium,
Magnesium, Phenol Red; In Vitro Technologies Pty Ltd, Australia), and centrifuged at 300 g for 15 min,
1600 g for 15 min, 16,000 g for 20 min at 4 ◦C. The supernatant was loaded on an SEC column and
100 µL fractions were collected. Fractions 7 to 11 were collected and concentrated to 100 µL using an
Amicon Ultra 0.5 Centrifugal Filter Unit (10 kDa, Merck Millipore, QLD, Australia) by centrifugation
at 14,000 g for 5 min at 4 ◦C.
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A commercial lyophilised sEV (exosome) standard isolated from ‘healthy’ participants
(Cat#: HBM-PESL; HansaBioMed, Lonza, QLD, Australia) was used as a control. However, the details
of the ‘healthy’ participants’ recruitment process are unknown, and their periodontal health status may
not have been determined. This sEV standard was isolated using the ultracentrifuge and ultrafiltration
combination method.
4.3. Salivary sEVs Characterisation
Following the recommendations of the International Society of Extracellular Vesicles [31],
sEVs were characterized by morphology, EV-associated protein markers, and size distribution, by TEM,
Western Blot and NTA, respectively.
For the transmission electron microscopy (TEM) analysis, sEV samples were fixed in 3% (w/v)
glutaraldehyde and analysed as previously described [40,41]. Briefly, 5 µL of each sample was adsorbed
on Formvar carbon-coated and glow-discharged electron microscopy grids. After washing with PBS,
the grids were transferred to a 50 µL drop of uranyl-oxalate solution, pH 7 for 3 mins. The grids were
imaged using a FEI Tecan 12-transmission electron microscope (FEI, Hillsboro, OR).
Protein concentration in sEVs was determined using a Pierce BCA Protein Assay Kit (ThermoFisher
Scientific, QLD, Australia) according to the manufacturer’s instructions. The samples (5 µL) were lysed
with RIPA buffer and mixed with BCA working solution, followed by incubation at room temperature
for 30 min. Absorbance was read at 562 nm on a Tecan Infinite M200 Pro spectrophotometer
(Tecan, Switzerland, QLD, Australia).
Western blot, as previously described [42–45], was used to determine the sEV-associated proteins
(CD 9 and ALIX). The sEV protein samples were separated by SDS-PAGE and transferred to
polyvinylidene difluoride membrane using a Trans-Blot®Turbo™ Transfer System (BioRad, QLD,
Australia). The membrane was blocked with Odyssey®Blocking Buffer at room temperature for
1 h and primary antibodies (CD9, 1: 1000, Santa Cruz Biotechnology; ALIX, 1: 1000, Santa Cruz
Biotechnology, QLD, Australia) were incubated overnight at 4 ◦C. After washing with 0.1% v/v Tween
20 in Tris-buffered saline (TBS), anti-rabbit DyLight 800 secondary antibody (1:10,000 in Odyssey
Blocking Buffer, QLD, Australia) and anti-mouse DyLight 700 secondary antibodies were added and
incubated for 1 h. The blots were visualised using a LI-COR Odyssey imaging system.
Nanoparticle tracking analysis was performed using a NanoSight NS500 instrument
(NanoSight, United Kingdom) using a 488 nm laser module and NTA software version 3.1. Polystyrene
latex beads (100 nm, Malvern NTA 4088) were used as a positive control and PBS was used as a
negative control. Samples (5 µL) were diluted 1:160 with DPBS for the NS500 instrument to measure
the rate of Brownian motion of nanoparticles in a light-scattering system. Five videos, each 30 s long
were captured for each sample with a camera level of 14 and a detection threshold set to five. Each
video file was processed and analysed to give the mean and mode of the particle sizes, along with the
concentration and the number of particles.
4.4. RNA Extraction and miRNA Expression by RT-qPCR
Total RNA was isolated from ~109 sEV particles using the Trizol method, following the
manufacturer’s instructions and as described previously [39]. The quality and quantity of RNA
were measured using a Tecan Infinite M200 Pro Spectrophotometer (TECAN, Australia).
Reverse transcription was performed using a miScript Reverse Transcription Kit (QIAGEN, Australia)
and real-time PCR was performed using a miScript SYBRGreenKit (QIAGEN, Australia) and ABI
StepOnePlus equipment. The primers for miRNAs (hsa-miR-15a-5p, hsa-miR-29b-3p, hsa-miR-124-3p,
hsa-miR-140-5p, hsa-miR-146a-5p, hsa-miR-148a-3p, hsa-miR-155-5p, hsa-miR-223-3p, hsa-miR-301b,
hsa-miR-628-5p) are listed in Table 2. The expression of each miRNA was normalized to the recommended
housekeeping genes, human small nucleolar RNA SNORD48 [46] and hsa-miR-16-5p [47]. CT values
>35 were excluded. ∆CT was calculated as the CTmiRNA target–CThousekeeping and the relative gene
expression data were presented as 2−∆CT.
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Table 2. The miRNA primers used in this study.













4.5. Discriminatory Power Analysis
Receiver Operating Characteristic (ROC) curves and the area under the curve (AUC) were used
to measure the discriminatory power of the upregulated miRNAs as biomarkers for periodontitis.
For each upregulated miRNA, the ROC curves were generated using the relative gene expression
levels of healthy controls and patients (gingivitis and periodontitis, respectively) by GraphPad Prism
8.3.1 software (San Diego, USA). Sensitivity, specificity, area under the curve (AUC, indicating the
discriminatory power of the biomarkers) and p values, were calculated by the software.
4.6. Statistical Analysis
The data are presented as the mean ± SD (standard deviation). The data between healthy,
gingivitis and periodontitis patients were determined by an ordinary one-way ANOVA analysis
in Prism 8.3.1. ROC curves and AUC were determined by the Wilson/Brown method between
healthy controls, and gingivitis and periodontitis, respectively. p < 0.05 was considered a statistically
significant difference.
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